论文部分内容阅读
现有的美国感染病协会(IDSA)发布的艰难梭菌感染(CDI)治疗指南在发表时,其中某些部分就已过时。例如缺乏核酸扩增试验(NAAT)在诊断方面的应用论证;使用粪便微生物群移植的方法治疗复发。同时在此期间也已出现了许多新信息,如新的治疗药物非达霉素(fidaxomicin)。因此IDSA正在更新该指南。同时欧洲临床微生物与感染病协会(ESCMID)也对2009年版指南进行更新。
Some of these guidelines are outdated when published by the current American Society of Infectious Diseases (IDSA) guidelines on treatment of C. difficile infection (CDI). For example, the lack of nucleic acid amplification test (NAAT) in the diagnosis of the application demonstration; use of fecal microbiota transplantation for the treatment of recurrence. In the meantime, there have also been many new information emerging, such as the new therapeutic drug fidaxomicin. IDSA is updating this guide. At the same time, the European Society for Clinical Microbiology and Infectious Diseases (ESCMID) also updated the 2009 edition of the guidelines.